Oclacitinib is a novel JAK inhibitor and also inhibits the function of Jak1 dependent cytokines in some anti allergic, inflammatory and pruritus reactions. The study confirmed that the experimental animals (dogs) took orally at the dose of 0.4-0.6mg/kg, twice a day, which was safe and effective in the treatment of pruritus caused by atopic dermatitis, and showed better efficacy than oral glucocorticoids. During treatment, olatinib alleviated itching within 24 hours, and more than 70% of the experimental animals reduced more than 50% of the itching reaction on day 7.